Syndax Pharmaceuticals (SNDX) Change in Receivables (2024 - 2026)

Syndax Pharmaceuticals' Change in Receivables history runs 3 years deep, the most recent figure standing at -$120000.0 for Q1 2026.

• In Q1 2026, Change in Receivables fell 101.48% year-over-year to -$120000.0; the TTM figure through Mar 2026 stood at $22.2 million (up 289.9% YoY), while the FY2025 annual figure was $30.4 million, up 736.15% from the prior year.
• Change in Receivables was -$120000.0 for Q1 2026 at Syndax Pharmaceuticals, down from $30.4 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $30.4 million in Q4 2025 to a low of -$11.8 million in Q3 2025.
• Historically, Change in Receivables has averaged $3.8 million across 3 years, with a median of $3.5 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Change in Receivables soared 23620.31% in 2025, then plunged 101.48% in 2026.
• A 3-year view of Change in Receivables shows it stood at $128000.0 in 2024, then jumped by 23620.31% to $30.4 million in 2025, then sank by 100.4% to -$120000.0 in 2026.
• The last three Change in Receivables figures came in at -$120000.0 (Q1 2026), $30.4 million (Q4 2025), and -$11.8 million (Q3 2025), per Business Quant data.